IGM Biosciences stock has experienced a significant decline, indicating an overall bearish sentiment in the market. The company's high expenses and poor financial management have devalued the company.

The iShares Expanded Tech Sector ETF (NYSEARCA:IGM) is a comprehensive ETF that gives investors exposure to the full spectrum of the North American tech sector, as it includes key tech-related stocks ...

Higher interest rates and worries about banking system stability and a recession have rocked the market and caused the energy and financial Sectors to sell off. Surprisingly enough to some investors, ...

IGM Financial Inc (TSX:IGM) is set to release its Q2 2025 earnings on Aug 6, 2025. The consensus estimate for Q2 2025 revenue is $0.81 billion, and the earnings are expected to come in at $1.02 per ...

4 analysts have expressed a variety of opinions on IGM Biosciences (NASDAQ:IGMS) over the past quarter, offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments ...

Based on the one-year price targets offered by 6 analysts, the average target price for IGM Financial Inc (TSX:IGM) is $50.67 with a high estimate of $56.00 and a low estimate of $47.00. The average ...

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies ...

Natural IgM, a pentameric, polyreactive antibody, is mainly secreted by peritoneal B1 B cells and recognizes and binds self antigens such as phospholipids. The unique structure of natural IgM allows ...

Mountain View, California-based IGM Biosciences, Inc. proposes to offer 10.938 million shares in an IPO at an estimated price range of $15-$17 per share, according to a S-1/A filing. The offering has ...